Skip navigation

Stay on the Pulse of New and Changing Regulatory Guidance * Ensure Compliance with the Big Four Federal Programs * Navigate the Evolving 340B Landscape

August 19-20, 2020
  • Philadelphia, PA

In its 12th year, the industry leading events on 340B and Federal Pricing and Reporting come together to advance the conversation and provide an in-depth look at the complexity of contracting with the “Big Four” federal programs and strategies to strengthen 340B program compliance. CBI’s 340B and Federal Reporting Congress is built for pharma/biotech drug companies of all stages and sizes and provides models and processes to ensure success and compliance. Benefit from the opportunity to hear directly from government officials and join the hundreds who have benefited from the invaluable learnings in a this highly complex market.

Leading Stakeholder Perspectives on Topics Including:

  • Policy proposals, regulatory oversight and compliance with the Big Four federal programs
  • Status of HRSA audits of manufacturers and covered entities
  • Country of Origin and Trade Agreement Act compliance
  • Single vs. dual pricing methodology strategies
  • Considerations for FSS contract preparation and implementation
  • Managing 340B refunds, overcharges and reconciliation processes

Previous Attendee Acclaim:

The lineup of speakers for the program were top notch.
The meeting was timely and gave plenty of opportunities
to network with attendees.

President, Apexus

As someone who works with VA, DOD and PHS, this program has consistently given me an update and preparation for the coming year.

Federal Accounts, Teva Pharmaceuticals

The CBI Conference was outstanding — very informative
and timely topics covering the hot industry trends.
Very worthwhile event to attend.

Executive Director, Finance, Merck

The program was beyond a value-add. The mix of knowledge with the presenters provided something for every participant.

Manager, Strategic Contracting, Johnson & Johnson

As always, CBI delivered a conference filled with
quality content and subject matter experts
in the government programs field.

Director, Contracts & Pricing, Acorda Therapeutics, Inc.

Timely and relevant information sharing from industry experts that have practical application I can take back to the office with me.

Government Pricing Analyst, AstraZeneca

12th Annual 340B and Federal Reporting Congress

Stay on the Pulse of New and Changing Regulatory Guidance * Ensure Compliance with the Big Four Federal Programs * Navigate the Evolving 340B Landscape

In its 12th year, the industry leading events on 340B and Federal Pricing and Reporting come together to advance the conversation and provide an in-depth look at the complexity of contracting with the “Big Four” federal programs and strategies to strengthen 340B program compliance. CBI’s 340B and Federal Reporting Congress is built for pharma/biotech drug companies of all stages and sizes and provides models and processes to ensure success and compliance. Benefit from the opportunity to hear directly from government officials and join the hundreds who have benefited from the invaluable learnings in a this highly complex market.

Leading Stakeholder Perspectives on Topics Including:

  • Policy proposals, regulatory oversight and compliance with the Big Four federal programs
  • Status of HRSA audits of manufacturers and covered entities
  • Country of Origin and Trade Agreement Act compliance
  • Single vs. dual pricing methodology strategies
  • Considerations for FSS contract preparation and implementation
  • Managing 340B refunds, overcharges and reconciliation processes

Previous Attendee Acclaim:

The lineup of speakers for the program were top notch.
The meeting was timely and gave plenty of opportunities
to network with attendees.

President, Apexus

As someone who works with VA, DOD and PHS, this program has consistently given me an update and preparation for the coming year.

Federal Accounts, Teva Pharmaceuticals

The CBI Conference was outstanding — very informative
and timely topics covering the hot industry trends.
Very worthwhile event to attend.

Executive Director, Finance, Merck

The program was beyond a value-add. The mix of knowledge with the presenters provided something for every participant.

Manager, Strategic Contracting, Johnson & Johnson

As always, CBI delivered a conference filled with
quality content and subject matter experts
in the government programs field.

Director, Contracts & Pricing, Acorda Therapeutics, Inc.

Timely and relevant information sharing from industry experts that have practical application I can take back to the office with me.

Government Pricing Analyst, AstraZeneca